AZN vs. NVO
Compare and contrast key facts about AstraZeneca PLC (AZN) and Novo Nordisk A/S (NVO).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: AZN or NVO.
Correlation
The correlation between AZN and NVO is 0.32, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
AZN vs. NVO - Performance Comparison
Key characteristics
AZN:
0.85
NVO:
-0.84
AZN:
1.21
NVO:
-1.07
AZN:
1.17
NVO:
0.86
AZN:
0.61
NVO:
-0.68
AZN:
1.28
NVO:
-1.49
AZN:
13.37%
NVO:
21.32%
AZN:
20.27%
NVO:
37.67%
AZN:
-48.94%
NVO:
-71.32%
AZN:
-14.91%
NVO:
-42.79%
Fundamentals
AZN:
$230.60B
NVO:
$366.23B
AZN:
$2.25
NVO:
$3.18
AZN:
32.80
NVO:
26.23
AZN:
0.88
NVO:
1.20
AZN:
$54.07B
NVO:
$290.40B
AZN:
$43.87B
NVO:
$245.88B
AZN:
$17.22B
NVO:
$148.56B
Returns By Period
In the year-to-date period, AZN achieves a 13.80% return, which is significantly higher than NVO's -2.65% return. Over the past 10 years, AZN has underperformed NVO with an annualized return of 11.24%, while NVO has yielded a comparatively higher 15.77% annualized return.
AZN
13.80%
9.71%
-13.19%
17.02%
10.93%
11.24%
NVO
-2.65%
3.34%
-38.82%
-29.99%
23.31%
15.77%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
AZN vs. NVO — Risk-Adjusted Performance Rank
AZN
NVO
AZN vs. NVO - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for AstraZeneca PLC (AZN) and Novo Nordisk A/S (NVO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
AZN vs. NVO - Dividend Comparison
AZN's dividend yield for the trailing twelve months is around 3.37%, more than NVO's 1.72% yield.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
AZN AstraZeneca PLC | 3.37% | 2.27% | 2.15% | 2.14% | 2.40% | 2.80% | 2.81% | 3.61% | 3.95% | 5.01% | 4.06% | 3.98% |
NVO Novo Nordisk A/S | 1.72% | 1.68% | 1.00% | 1.20% | 1.34% | 1.86% | 2.14% | 2.47% | 2.12% | 3.93% | 1.31% | 1.96% |
Drawdowns
AZN vs. NVO - Drawdown Comparison
The maximum AZN drawdown since its inception was -48.94%, smaller than the maximum NVO drawdown of -71.32%. Use the drawdown chart below to compare losses from any high point for AZN and NVO. For additional features, visit the drawdowns tool.
Volatility
AZN vs. NVO - Volatility Comparison
The current volatility for AstraZeneca PLC (AZN) is 5.76%, while Novo Nordisk A/S (NVO) has a volatility of 13.07%. This indicates that AZN experiences smaller price fluctuations and is considered to be less risky than NVO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
AZN vs. NVO - Financials Comparison
This section allows you to compare key financial metrics between AstraZeneca PLC and Novo Nordisk A/S. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities